Recently, according to the third circuit memorandum of the United States Court of Appeals, lawyers for Logic company alleged that the director of the Center for Tobacco Products (CTP) at the Food and Drug Administration (FDA), Brian King, allowed for the dismissal of recommendations from FDA scientists and revoked the market approval for Logic Technology's menthol electronic cigarette products.
A motion has been filed with Logic Corporation to suspend the marketing injunction (MDO) against its menthol e-cigarette products, and new documents have been provided to the company.
According to lawyers from Troutman Pepper, new documents being reviewed by Vapor Voice reveal an unusual fact: the Center for Tobacco Products' (CTP) Office of Science (OS) revoked its science-based recommendations for the marketing authorization order of Logic's mint-flavored electronic cigarette (ENDS) prior to its pre-market tobacco product application (PMTA) being approved, after pressure from the new CTP director and the Office of Compliance and Enforcement's (OCE) center director.
According to Logic's lawyer, the company claims the right to retain their mint-flavored product in the MDO of the institution because the Office of the Center Director (OCD) overturned the Office of Science's (OS) approval of Logic's "science-based assessment" and preliminary recommendation for their product. However, the memorandum states that mint is classified as a product that will be "disfavored", and Logic is seeking court recognition that the institution's actions, based on an "unpublished, comprehensive policy" and "product-specific decisions" that were not subject to notice or comment rules, were "arbitrary and capricious".
In the October 25 memo, the operating system stated that it evaluated Logic Company's pre-market tobacco product application (PMTA), including its product-specific evidence, and concluded that the authorization of marketing Logic's menthol-flavored ENDS is appropriate for protecting public health (APPH). However, the memo reveals that the operating system only changed course after the director of the new Center for Tobacco Products (CTP) and the Office of Center Director (OCD) reached the conclusion that menthol-flavored ENDS should be considered a "disfavored" product category despite conflicting evidence, as reported by the Office of Science (OS).
The OS memorandum stated, "From a policy perspective, at the time, OS believed that as long as menthol cigarettes were still on the market, menthol-flavored ENDS could directly replace them, providing a less harmful alternative for smokers of menthol cigarettes. Compared to non-menthol smokers, they were less likely to successfully quit smoking.
According to OS, this suggests that there are potential benefits in increasing usage and transition opportunities, and evidence specific to certain products suggests that even ENDS products that are no greater than tobacco-flavored could have a greater potential for smoking cessation or significant reduction in smoking.
Subsequently, OCD raised questions about OS's recommendations, including the adequacy and relevance of scientific literature regarding the differing preferences of adult menthol smokers for menthol, ultimately indicating possible behavioral changes. OCD also highlighted concerns about the significant appeal of menthol to young people. As of July 2022, the decision on Logic PMTA was still pending when CTP transitioned to Brian King as the new center director.
According to a memorandum, OS shared their views with the newly appointed center director and openly discussed various topics including literature, clinical studies related to Logic, usage risks, and potential post-marketing requirements. Following the meeting, a senior scientific consultant specializing in OCD shared their perspective with OS, highlighting the significant risks to young people and the lack of evidence supporting the practical difference between using tobacco flavoring versus menthol flavoring. As a result, the approach to menthol flavoring should be the same as other flavorings, only approving products if evidence shows that the benefits of menthol flavoring outweigh the risks to young people. This led OS to change their direction and their approval of Logic marketing.
The second memo restated the same policy shift and suggested convening a meeting to address concerns raised by operating system personnel about the appropriateness of the decision-making process behind the refusal of Logic peppermint PMTA. The operating system also expressed concern that the new OCD method would eliminate all ENDS products that do not contain tobacco flavors.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
